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Figure S1. Cumulative distribution of AAO in discovery studies, showing how GenRED distribution (red 
line) was scaled due to ascertainment on age at onset of 30 or less. 
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Figure S2. Analysis strategy of MDD cases by overlapping subsets of AAO.  
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Figure S3. Distribution of age at onset in discovery samples. 
  
Power et al.  Supplement 
 
5 
 
 
Figure S4. Manhattan, QQ, and SNAP plots for rs7647854 in O5-8 of the discovery samples. 
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Figure S5. Forest plot of effect sizes (odds ratios) for rs7647854 in 50% latest-onset cases against 
controls across eight discovery studies (above horizontal line; GenRED not included) and nine replication 
studies (below line).   
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Figure S6. By-study association analysis of rs7647854, following the one-year sequential addition 
method of Macgregor et al. (1). For each discovery study, the figure shows the odds ratio for association 
in a case control study, where only cases onset above the AAO indicated on the x-axis are included in the 
analysis.  Analysis was terminated when fewer than 100 cases remained.  Analysis shows consistency of 
effect across studies, with the OR increasing when only older-onset cases are included. 
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Figure S7. Polygenic risk score of schizophrenia and bipolar disorder within MDD stratifying by both age 
at onset and age at interview (AAI). The results show the increased overlap with bipolar disorder (BP) 
and schizophrenia (SCZ) in early-onset MDD (O1-3) was not driven by cases with earlier AAI (in fact the 
opposite). This tentatively suggests it reflects true genetic overlap rather than misdiagnosed MDD cases 
that eventually develop SCZ or BP. AAI of 44 was used a cut-off as this was the median of the sample. 
We calculated the proportion of variance explained (Nagelkerke’s R2) by subtraction of a full model 
(covariates + RPS) score from a reduced model (covariates only). 
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Supplemental Tables 
 
Table S1. Genotyping and Imputation status of rs7647854 by study with info score. 
Stage Study Genotyped? Info 
Discovery GAIN Genotyped N/A 
Discovery GSK Genotyped N/A 
Discovery MDD2K_600k Mixed 0.89 
Discovery MDD2K_317k Mixed 0.81 
Discovery MPIP Genotyped N/A 
Discovery RADIANT_Bonn/Mannheim Genotyped N/A 
Discovery RADIANT_UK Genotyped N/A 
Discovery STAR*D Imputed 0.62 
Replication TwinGene Genotyped N/A 
Replication PsyCoLaus Imputed 0.8959 
Replication SHIP-LEGEND Imputed 0.87 
Replication GenRED2/DepGenesNetworks Genotyped 0.94 
Replication deCODE Mixed 0.997 
Replication University of Münster Genotyped N/A 
Replication Combined Danish Mixed 1.01 
Replication Generation Scotland Genotyped N/A 
Replication Converge Mixed 0.98 
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Table S2. Results from polygenic score analysis using the genetic association results from the PGC Bipolar 
Disorder (2), PGC Schizophrenia (3), GERAD1 Alzheimer’s disease (4), and CARDIoGRAM coronary heart disease 
(CAD) (5). GWAS to score into MDD discovery studies (excluding GenRED and Bonn-Mannheim). We calculated 
the proportion of variance explained (Nagelkerke’s R2 for logistic regression and R2 for linear regression; reported 
as a percentage) by subtraction of a full model (covariates + RPS) score from a reduced model (covariates only). 
All results presented were corrected for sex, 20 population principal components and study indicators.  
Subset Bin p-value Threshold 
Bipolar Disorder  Schizophrenia  Alzheimer’s Disease 
 CAD 
R2 (%) p-value  R2 (%) p-value  R2 (%) p-value  R2 (%) p-value 
Youngest 3/8 
v. controls 
1 0.001 0.2 4.13*10-4  0.1 2.23*10-3  <0.01 0.695  <0.01 0.562 
2 0.01 0.4 3.39*10-8  0.7 2.60*10-12  <0.01 0.415  <0.01 0.746 
3 0.1 0.5 1.61*10-9  0.8 1.05*10-13  <0.01 0.542  0.1 0.067 
4 0.2 0.5 4.81*10-9  0.8 1.59*10-13  <0.01 0.686  0.1 0.044 
5 0.3 0.5 7.06*10-10  0.9 1.24*10-14  <0.01 0.923  0.1 0.032 
6 0.4 0.6 7.00*10-11  0.9 2.89*10-15  <0.01 0.906  0.1 0.012 
7 0.5 0.6 5.75*10-11  0.9 2.22*10-15  <0.01 0.868  0.1 0.013 
Oldest 3/8 
v. controls 
1 0.001 <0.01 0.022  <0.01 0.380  <0.01 0.688  <0.01 0.602 
2 0.01 0.1 4.52*10-3  0.10 5.69*10-3  <0.01 0.433  <0.01 0.505 
3 0.1 0.1 9.61*10-4  0.10 4.10*10-3  <0.01 0.199  0.1 0.062 
4 0.2 0.1 1.22*10-3  0.10 5.37*10-3  <0.01 0.201  0.1 0.029 
5 0.3 0.1 7.90*10-4  0.10 5.75*10-3  <0.01 0.346  0.1 0.018 
6 0.4 0.1 7.28*10-4  0.10 9.31*10-4  <0.01 0.385  0.1 0.012 
7 0.5 0.1 4.52*10-4  0.10 8.24*10-4  <0.01 0.223  0.1 0.017 
All cases v. 
controls 
Cases only 
included if 
had age of 
onset 
information 
1 0.001 0.1 1.94*10-4  0.10 1.83*10-3  <0.01 0.811  <0.01 0.262 
2 0.01 0.1 6.13*10-8  0.40 1.05*10-11  <0.01 0.544  <0.01 0.223 
3 0.1 0.3 1.63*10-9  0.50 1.23*10-13  <0.01 0.424  <0.01 4.28*10-3 
4 0.2 0.3 9.59*10-9  0.50 1.38*10-13  <0.01 0.402  0.1 8.01*10-4 
5 0.3 0.3 3.61*10-10  0.50 1.13*10-14  <0.01 0.758  0.1 5.34*10
-4 
6 0.4 0.4 1.43*10-10  0.60 2.22*10-16  <0.01 0.852  0.1 1.84*10
-4 
7 0.5 0.4 5.93*10-11  0.60 2.22*10-16  <0.01 0.753  0.1 2.57*10
-4 
Youngest 3/8 
v. Oldest 3/8 
1 0.001 <0.010 0.252  <0.00 0.073  <0.01 0.564  <0.01 0.989 
2 0.01 0.1 0.016  0.30 5.58*10-4  <0.01 0.907  <0.01 0.779 
3 0.1 0.1 0.019  0.30 1.44*10-4  <0.01 0.408  <0.01 0.818 
4 0.2 0.1 0.029  0.30 2.10*10-4  <0.01 0.307  <0.01 0.815 
5 0.3 0.1 0.011  0.40 5.25*10-5  <0.01 0.342  <0.01 0.756 
6 0.4 0.2 6.31*10-3  0.30 1.83*10-4  <0.01 0.270  <0.01 0.875 
7 0.5 0.1 6.60*10-3  0.30 1.67*10-4  <0.01 0.157  <0.01 0.947 
AAO as 
continuous 
trait 
1 0.001 0.03 0.144  0.01 0.440  0.01 0.455  <0.01 0.692 
2 0.01 0.09 8.16*10-3  0.09 0.010  <0.01 0.799  <0.01 0.781 
3 0.1 0.09 7.82*10-3  0.11 3.89*10-3  0.01 0.346  <0.01 0.595 
4 0.2 0.10 6.07*10-3  0.10 6.21*10-3  0.02 0.269  <0.01 0.636 
5 0.3 0.10 4.55*10-3  0.13 1.19*10-3  0.01 0.347  <0.01 0.765 
6 0.4 0.11 2.83*10-3  0.11 2.82*10-3  0.02 0.244  <0.01 0.852 
7 0.5 0.11 3.21*10-3  0.12 2.52*10-3  0.03 0.125  <0.01 0.954 
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Table S3. Results of the GCTA analysis estimating the variance captured by genotyped SNPs in early-
onset cases (O1-3) and late-onset cases (O6-8). No difference in SNP-heritability was observed across 
early and late-onset MDD. A bivariate model looking at the overlap of heritability between early and late 
onset cases when both compared to controls separately gave a genetic correlation (rG) of 99.77%.  
  All Cases  Recurrent Cases 
Cases Controls Cases hp2 (SE) p-value  Cases hp2 (SE) p-value 
O1-O3 9519 3969 0.220 (0.036) 4x10-11  3120 0.245 (0.042) 1x10-9 
O6-O8 9519 2779 0.231 (0.046) 1x10-7  1968 0.262 (0.059) 2x10-6 
 
 
Table S4. Associations of rs7647854 with other conditions. 
SNP Chr. Ref. allele 
Discovery  Alzheimer's GWAS  CAD GWAS 
OR P  OR P  OR P 
rs7647854 3 G 1.30 3.4x10-11 
 
0.95 0.19 
 
1.04 0.04 
 
 
Supplemental Methods 
Genome-wide Complex Trait Analysis  
In order to estimate the heritability of AAO within MDD, Genome-wide Complex Trait Analysis (GCTA) 
was used to estimate the proportion of AAO phenotypic variance explained by common SNPs across the 
genome (6). SNPs were included with MAF > 0.01 and imputation R2 > 0.6 in all nine studies, leaving a 
total of 962,903 SNPs. One individual was removed from each pair of individuals sharing more than 5% 
of their genetic material. Two analyses were run, analyzing cases in O1-3 against all controls and O6-8 
cases against all controls. Each analysis was also run restricting to cases with recurrent depression only. 
Study indicators, twenty principal components and sex were included as covariates. Prevalence for MDD 
was set at 16.5% from Kessler et al. (8). A bivariate model was implemented within GCTA to examine the 
genetic covariance between early onset (O1-3) cases and later onset cases (O6-8). Controls were 
randomly split between the two groups and did not different significantly based on gender or originating 
study. Bivariate analysis was run covarying for 20 population principal components, study indicators and 
gender. Results are outlined in Table S1. 
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Description of Replication Studies 
PsyCoLaus 
Subjects were selected from subjects of European ancestry from a community survey (CoLaus) carried 
out in the city of Lausanne, Switzerland (9). Subjects were randomly selected from a complete list of the 
Lausanne inhabitants aged 35-75 years. All 35 to 66-year old participants were invited by letters also to 
participate in the psychiatric evaluation (PsyCoLaus) (10). Sixty-seven percent of the participants of the 
CoLaus study in the age range between 35-66 years accepted the psychiatric evaluation, which resulted 
in a sample of 3,719 individuals, of whom 92% were of European ancestry. Psychiatric assessment in the 
PsyCoLaus sub-study included the semi structured Diagnostic Interview for Genetic Studies (DIGS), 
French version (11). Cases met DSM-IV criteria for MDD and controls were devoid of any psychiatric 
disorders. A subset of the 3,419 European subjects who received full psychiatric assessment and gave 
consent for genetic testing were selected for GWAS genotyping. This research was approved by the local 
institutional review board. All participants received a detailed description of the goal and funding of the 
study and signed a written informed consent. 
SHIP-LEGEND 
Data from the Study of Health in Pomerania (SHIP) were used (12; 13). The target population was 
comprised of adult German residents in northeastern Germany living in 3 cities and 29 communities, 
with a total population of 212,157. A two-stage stratified cluster sample of adults aged 20-79 years 
(baseline) was randomly drawn from local population registries. The net sample (without migrated or 
deceased persons) comprised 6,267 eligible subjects of whom 4,308 Caucasian subjects participated at 
baseline SHIP-0 between 1997 and 2001. Follow-up examination (SHIP-1) was conducted 5 years after 
baseline and included 3,300 subjects. In 2007, the “Life-Events and Gene-Environment Interaction in 
Depression” (LEGEND) study was started based on SHIP (14). The lifetime diagnosis of MDD was 
assessed with the Munich-Composite International Diagnostic Interview (M-CIDI). The M-CIDI is a 
standardized fully structured instrument for assessing psychiatric disorders over the life span according 
to DSM-IV criteria. The computerized version of the interview was used by clinically experienced 
interviewers (psychologists) in a face-to-face situation. All interviewers had undergone intensive and 
continuous training in the diagnostic procedures. SHIP and LEGEND were approved by the local 
Institutional Review Board and conformed to the principles of the Declaration of Helsinki.  
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TwinGene 
The TwinGene project, conducted between 2004 and 2008, is a population-based Swedish study of twins 
born between 1911 and 1958 drawn from the Swedish Twin Registry (15). All subjects in this 
investigation were independent (i.e., one twin selected per twin pair). The study participants previously 
participated in a telephone interview called Screening Across the Lifespan Twin Study (SALT). Data from 
the SALT study were used to identify MDD cases as either reporting antidepressant use or meeting DSM-
IV criteria for MDD using the Composite International Diagnostic Interview Short Form (CIDI-SF) criteria. 
The study was approved by the local ethics committee at Karolinska Institutet and all participants gave 
informed consent.  
Genetics of Recurrent Early-Onset Depression Phase II & Depression Genes and Networks 
The second phase of GenRED was included as a replication sample (the first phase was a discovery 
sample). GenRED2 included new cases meeting the same criteria as in GenRED, plus new controls. Dr. 
Janet Sobell (University of Southern California) contributed 287 post-QC controls from the Mayo DNA 
Bank which consists of long-term, community medicine patients (Mayo Clinic, Rochester, MN) who were 
undergoing venipuncture for any reason. Consenting individuals ages 45 and above completed a brief 
demographic and psychiatric screening questionnaire. Extensive medical records were screened for 
evidence of psychiatric illness. Individuals were excluded if they were judged likely to have had a mood 
or psychotic disorder on the basis of a review of medical records, taking into account the recorded 
diagnoses and treatment in each case (including major disorders as well as possible proxies for a mood 
disorder in older nomenclature such as adjustment disorders, depression NOS, anxiety state, etc.). The 
final subset was selected to roughly match the proportions of self-reported ancestry in the GenRED 1+2 
sample. Drs. Carlos Pato and James Knowles contributed 187 post-QC controls from the Genomic 
Psychiatry Consortium, an ongoing study of schizophrenia and bipolar disorder. Controls were recruited 
opportunistically in the Los Angeles area and screened with a self-report questionnaire. We selected 
individuals who reported European ancestry in all grandparents and answered negatively to five 
screening questions for lifetime bipolar disorder, five for lifetime schizophrenia, and four for lifetime 
MDD. Note that these 1,305 subjects were genotyped at the same lab (Centrillion Biosciences, Mountain 
View, CA) and with the same GWAS array (Illumina Omni1-Quad) as the Depression Genes and Networks 
sample (below) collected by a subset of the GenRED investigators, so that these samples were combined 
for the PGC replication analysis.  
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The Depression Genes and Networks (DGN) sample was genotyped and analyzed in combination 
with the GenRED2 sample (above). A survey research company (Knowledge Networks, Menlo Park, CA) 
recruited the 471 post-QC recurrent MDD cases and 470 never-depressed controls from participants in 
an online survey panel that is recruited on an ongoing basis using random digit dialing of nationally-
representative US households. (Note that the same panel was used to recruit the Molecular Genetics of 
Schizophrenia control sample for the NIMH repository, but individuals who were invited to be screened 
for MGS and who were still members of the panel were not invited to be screened for DGN.) Online 
screening was carried out using the CIDI-SF depression and alcohol and substance dependence modules; 
prospective controls were selected who reported two or more episodes meeting criteria for MDD but 
denied lifetime substance dependence, while prospective controls denied ever having two or more 
weeks of depressed mood or anhedonia and two or more other MDD criteria outside of acute 
bereavement. These individuals were then interviewed (SCID) and individuals not meeting the initial 
eligibility criteria (based on final review by the site PI) were excluded. Note that these cases all reported 
recurrent MDD, but were not required to meet the additional criteria required for the GenRED project. 
Danish Replication Sample 
The Danish replication sample was made up of samples from 3 sources: additional RADIANT cases 
recruited in Denmark with genotype data available; a subset of Danish cases and screened controls 
recruited for the DEMO and PRISME studies genotyped specifically for these SNPs; and a cohort of 
unscreened controls from the Danish population already genotyped and imputed. As each sample 
individually was relatively small and minor allele frequencies were roughly in line across all samples, 
they were combined in their analysis. 
The combined DEMO and PRISME samples came from 3 cohorts. The Denmark 1 cohort includes 
162 cases with depression according to the ICD-10 diagnostic criteria. Diagnoses were obtained using a 
semi-structured diagnostic interview (Schedules for Clinical Assessment in Neuropsychiatry (SCAN 
version 2.1)). The subjects were all part of the Danish PRISME study and employees within large public 
service workplaces in a Danish county (16; 17). The Denmark 2 and 3 cohort includes 104 and 70 
individuals from the Danish DEMO trial 1 and 2, respectively. The Denmark 2 cohort is described in detail 
by Krogh et al. (18; 19). All cases fulfilled the ICD-10 diagnostic criteria for depression and the diagnoses 
were obtained using the Major Depression Inventory (MDI) (20). The control sample consisted of 289 
healthy, screened individuals with no diagnoses of affective disorders or anxiety disorders. The controls 
were all part of the Danish PRISME study. All cases and controls were Caucasian of origin and gave 
written informed consent. This study was approved by the Danish Data Protection Agency and the ethics 
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committees in Denmark. Genotyping for SNPs was done within this sample specifically for those 
requiring replication, as genome-wide data was not available. PCR reactions were composed of 10 ng 
DNA in a total volume of 9 µl. DNA amplification was performed as a multiplex reaction with either two 
(rs9323497 and rs7647854), two (rs10184299 and rs7950328) or four (rs625527, rs7807320, rs4379463 
and rs1969420) markers simultaneously, except for rs1276324, which was amplified alone. Following 
PCR, primers and nucleotides were degraded by treatment with exonuclease and shrimp alkaline 
phosphatase and a primer extension reaction was performed according to the SNaPshot protocol using 
fluorescently labeled nucleotides (Applied Biosystems, Fostercity, USA). Genotyping was performed on 
an ABI 3130 Prism Genetic Analyzer, and the fluorescent peaks were analysed using Genemapper 
version 4.0 (Applied Biosystems, Fostercity, CA) and independently checked by two experienced 
investigators. Additional method conditions and primer sequences are available on request. 
The 155 RADIANT cases were ascertained from two studies: DeNT, a retrospective study of 
depression in sibling pairs; and GENDEP, a pharmacogenetic study of antidepressant response. Both 
studies required moderate to severe depression as diagnosed by DSM-IV or ICD-10 criteria, with DeNT 
further requiring at least 2 episodes over their lifetime. All cases were recruited in Aarhus. Individuals 
were excluded if their genotypic data showed a missing rate >1%, abnormal heterozygosity, a sex 
assignment that conflicted with phenotypic data, if they were related (up to second degree) with other 
study members, or were of non-European ancestry. SNPs with a low minor allele frequency (<1%) or 
showing departure from Hardy–Weinberg equilibrium (p < 1E-5) were excluded. No imputation method 
was used. Full details of genotyping methods and quality control procedures has been published 
previously, with respect to the UK subset of the RADIANT studies (21).  
The final cohort of Danish individuals were 883 controls from a schizophrenia GWAS conducted 
in Denmark on all individuals born in Denmark since 1981 having a schizophrenia diagnosis in the 
nationwide Danish Psychiatric Central Register as of 2006 (22). The controls were matched on sex, date 
of birth and age, and had no history of schizophrenia on the date of first diagnosis of schizophrenia of 
the case. By this procedure 915 controls were identified and subsequently dried blood spots from the 
individuals were obtained from the Danish Newborn Screening Biobank (DNSB) (23). Sufficient biological 
material was available for 899 controls. DNA was extracted from the dried blood spots using Extract-N-
Amp Blood PCR kit (Sigma Aldrich) and subsequently whole-genome-amplified in triplicates using the 
RepliG kit (Qiagen) (24). The three separate reactions were pooled before genotyping, which was done 
using the Illumina Human 610-quad beadchip. Altogether 883 controls were successfully genotyped. 
SNPs with a deviation from Hardy-Weinberg equilibrium (p < 0.0001) and a MAF below 0.01 were 
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excluded as were SNPs and individuals with more than 2% missing data. Furthermore, test for 
relatedness, estimation of individual heterozygosity and test for non-random missingness of SNPs 
between cases and controls were conducted.  One individual was excluded this way, leaving 882. 
Imputation was conducted using  Impute v2.3.0 using standard settings and based on 1000 genome v3 
and the strand file provided at the impute web site (25). 
University of Münster Depression Cohorts 
Data were pooled from the Münster Neuroimaging study and the Moodinflame study recruited from the 
same geographical area conducted at the Department of Psychiatry, University of Münster, Germany. 
From the Münster Neuroimaging Study, 516 healthy subjects, all adult, participated in the present study. 
All included subjects were thoroughly investigated by experienced psychologists and were free from any 
lifetime history of psychiatric disorders according to DSM-IV criteria (26), as ascertained by the SCID 
interview (27). Additional scales were employed (e.g., CTQ, LEQ, BDI). Exclusion criteria were scores ≥ 10 
on the Beck Depression Inventory (BDI) (28), any neurological abnormalities, history of seizures, head 
trauma or unconsciousness, intake of any psychotropic medication, and the usual MRI contraindications. 
Depression cases were derived from two Münster Depression cohorts (Moodinflame and Münster 
Neuroimaging Study). As part of the Münster Neuroimaging Study of depression, 167 depressed adult 
subjects recruited since 2005 at the University of Münster, Germany. All included subjects were 
thoroughly investigated by experienced psychologists and major depressive disorder (MDD) was 
ascertained according to DSM-IV criteria (24), as diagnosed with the SCID interview (25). Patients were 
recruited from the inpatient service of the University of Münster’s Department of Psychiatry. Exclusion 
criteria were any neurologic abnormalities; substance-related disorders; psychotic symptoms; a history 
of mania or hypomania; treatment with benzodiazepine; and previous electroconvulsive therapy; and 
the usual MRI-contraindications. Clinical assessment included a minimum of measures such as HAM-D-
21, BDI, number of episodes of depression, age of onset, duration of illness, medication history, 
education age and sex. According to similar inclusion and exclusion criteria, a second cohort 
(Moodinflame) of 238 adult cases was also recruited at the University of Münster, Germany, as part of 
the Moodinflame study. Psychiatric diagnoses were ascertained using a structured clinical interview 
(SCID) (25). Clinical and pathological features were assessed in a standardized manner using various 
scales among which were Inventory of Depressive Symptoms - Clinician Rated (IDS-C), Young Mania 
Rating Scale (YMRS), Childhood Trauma Questionnaire (CTQ), HAM-D, medication and psychiatric 
history. In addition to age, sex, and education, clinical characteristics such as number of episodes of 
depression, age of onset of depression, duration of illness and medication history were assessed.  
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Genotyping was conducted blind to phenotypic data. The ABI PRSIM 7900HT Sequence 
Detection System (Applied Biosystems Inc., Foster City, CA, USA) was used to genotype using KASPtm 
genotyping assays (LGC Genomics Ltd, Hoddesdon, Herts, UK). Positive and negative controls were 
included four times on each 384-well plate run, and 100 samples were run in duplicate for each assay 
(with no conflicts). Deviation from Hardy Weinberg equilibrium was tested using chi-squared tests.  
deCODE 
Cases and controls were all Icelandic and were recruited from all over Iceland. For patients, diagnoses 
were assigned according to DSM-III or ICD-10 criteria. Controls were recruited as a part of various 
genetic programs at deCODE (excluding the schizophrenia, bipolar disorder, and anxiety projects) and 
were not screened for psychiatric disorders. Age at onset was obtained from hospital records and was 
defined as the age at first hospital admission. Approval for the study was granted by the National 
Bioethics Committee of Iceland and the Icelandic Data Protection Authority. Informed consent was 
obtained for all participants. 
CONVERGE 
CONVERGE (CONVERGE: China Oxford and VCU Experimental Research on Genetic Epidemiology) is a 
collaboration between the University of Oxford, Hua Shan Hospital at Fudan University, China, and 
Virginia Commonwealth University.  Recurrent MD cases and controls were recruited from 53 provincial 
mental-health centers in China, were exclusively female and of Han Chinese ancestry. Critically, sampled 
controls have been carefully screened to ensure a low liability to depressive illness (>30 years old). 
Genetic material was extracted from saliva samples; sparse genome sequencing (~1.2X) was conducted 
for 12,000 cases and controls by Beijing Genomics Institute (BGI). Stringent quality control measures 
were implemented, with consideration to individual- and SNP-level metrics. 
Generation Scotland 
GS:SFHS consists of over 24,000 participants recruited at random from general medical practices across 
Scotland between 2006 and 2011. Probands (n = 7,953) were aged between 35 and 65 years and 
were registered with participating general medical practitioners. These individuals were not ascertained 
on the basis of having any particular disorder. Eligibility criteria specified that participants were over 18 
years of age and had one first-degree relative also willing to participate. 20,223 individuals had 
phenotypic information for major depressive disorder (cases n = 2751, controls n = 17472; 
www.generationscotland.org/) (29; 30). Genome-wide SNP data were ascertained for 10,000 individuals, 
and after quality control, genotype data was available for 9863 participants. 18.1% of the genotyped 
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individuals had a diagnosis of single or recurrent episode depression. A shared family identity number 
was given to groups where each member was a first-degree relative of at least one other person. The 
current sample of unrelated individuals was ascertained by removing individuals with a shared family ID. 
Individuals with depression were preferentially selected from families. A diagnosis of MDD was made 
using the Structured Clinical Interview for DSM-IV Disorders (SCID); trained researchers administered the 
screening questions after a period of training and reliability assessment. Participants who screened 
positive (21.7%) were invited to continue the interview that focused on mood disorders, from which 
information on the presence or absence of a lifetime history of MDD, age of onset and number of 
depressive episodes was provided. 
GERAD1 Consortium Study Description 
Cases and elderly screened controls were recruited by the Medical Research Council (MRC) Genetic 
Resource for AD (Cardiff University; Institute of Psychiatry, London; Cambridge University; Trinity 
College Dublin), the Alzheimer’s Research UK (ARUK) Collaboration (University of Nottingham; University 
of Manchester; University of Southampton; University of Bristol; Queen’s University Belfast; the Oxford 
Project to Investigate Memory and Ageing (OPTIMA), Oxford University); Washington University, St 
Louis, United States; MRC PRION Unit, University College London; London and the South East Region AD 
project (LASER-AD), University College London; Competence Network of Dementia (CND) and 
Department of Psychiatry, University of Bonn, Germany; the National Institute of Mental Health (NIMH) 
AD Genetics Initiative. 6,129 population controls were drawn from large existing cohorts with available 
GWAS data, including the 1958 British Birth Cohort (1958BC) (http://www.b58cgene.sgul.ac.uk), the 
KORA F4 Study and the Heinz Nixdorf Recall Study. All AD cases met criteria for either probable (NINCDS-
ADRDA, DSM-IV) or definite (CERAD) AD. All elderly controls were screened for dementia using the 
MMSE or ADAS-cog, were determined to be free from dementia at neuropathological examination or 
had a Braak score of 2.5 or lower. Genotypes from all cases and 4,617 controls were previously included 
in the AD GWAS by Harold and colleagues (4). Genotypes for the remaining 2,660 population controls 
were obtained from WTCCC2. Imputation of the dataset was performed using IMPUTE2 and the 1000 
genomes (http://www.1000genomes.org/) Dec2010 reference panel (NCBI build 37.1). The imputed 
data were then analyzed using logistic regression including covariates for country of origin, sex, age and 
3 principal components obtained with EIGENSTRAT software based on individual genotypes for the 
GERAD study participants.  
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for Neuropsychiatric Genetics and Genomics, Neurosciences and Mental Health Research Institute, 
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UK; Simon Lovestone, John Powell, Petroula Proitsi, and Michelle K. Lupton, Department of 
Neuroscience, Institute of Psychiatry, Kings College London, London, UK; Carol Brayne, Institute of Public 
Health, University of Cambridge, Cambridge, UK; David C. Rubinsztein, Cambridge Institute for Medical 
Research, University of Cambridge, Cambridge, UK; Michael Gill, Brian Lawlor, and Aoibhinn Lynch, 
Mercer’s Institute for Research on Aging, St. James’ Hospital and Trinity College, Dublin, Ireland; Kevin 
Morgan, and Kristelle Brown, Institute of Genetics, Queen’s Medical Centre, University of Nottingham, 
Nottingham, UK; Peter Passmore, David Craig, Bernadette McGuinness, and Stephen Todd, Ageing 
Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen’s 
University Belfast, Belfast, UK; Clive Holmes, Division of Clinical Neurosciences, School of Medicine, 
University of Southampton, Southampton, UK; David Mann, Clinical Neuroscience Research Group, 
Greater Manchester Neurosciences Centre, University of Manchester, Salford, UK; A. David Smith, 
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Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK; John Hardy, Department of Molecular 
Neuroscience and Reta Lilla Weston Laboratories, Institute of Neurology, London, UK; Simon Mead, MRC 
Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; Nick 
Fox, and Martin Rossor, Dementia Research Centre, Department of Neurodegenerative Diseases, 
University College, London, Institute of Neurology, London, UK; John Collinge, MRC Prion Unit, 
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; Wolfgang Maier, 
Frank Jessen, Reiner Heun, and Heike Kölsch, Department of Psychiatry, University of Bonn, Bonn, 
Germany; Britta Schürmann, Department of Psychiatry, and Institute for Molecular Psychiatry, 
University of Bonn, Bonn, Germany; Hendrik van den Bussche, Institute of Primary Medical Care, 
University Medical Center Hamburg Eppendorf, Germany; Isabella Heuser, Department of Psychiatry, 
Charité, Berlin, Germany; Johannes Kornhuber, Department of Psychiatry, University of Erlangen, 
Nürnberg, Germany; Jens Wiltfang, LVR Hospital Essen, Department of Psychiatry and Psychotherapy, 
University Duisburg-Essen, Germany; Martin Dichgans, Institute for Stroke and Dementia Research, and 
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Department of Neurology, Klinikum der Universität München, Munich, Germany; Lutz Frölich, Central 
Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany; Harald 
Hampel, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University, 
Frankfurt, Germany; Michael Hüll, Centre for Geriatric Medicine and Section of Gerontopsychiatry and 
Neuropsychology, Medical School, University of Freiburg, Germany; Dan Rujescu, Alzheimer Memorial 
Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig-Maximilian University, 
Munich, Germany; Alison Goate, Departments of Psychiatry, Neurology and Genetics, Washington 
University School of Medicine, St. Louis, MO, USA; John S.K. Kauwe, Department of Biology, Brigham 
Young University, Provo, UT, USA; Carlos Cruchaga, Petra Nowotny, John C. Morris, and Kevin Mayo, 
Departments of Psychiatry, Neurology and Genetics, Washington University School of Medicine, St. 
Louis, MO, USA; Gill Livingston, Nicholas J. Bass, Hugh Gurling, and Andrew McQuillin, Department of 
Mental Health Sciences, University College London, London, UK; Rhian Gwilliam, and Panagiotis 
Deloukas, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, 
UK; Markus M. Nöthen, Department of Genomics, Life and Brain Center, University of Bonn, Bonn, 
Germany; Peter Holmans, Michael O’Donovan, Michael J. Owen, and Julie Williams, Medical Research 
Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Neurosciences and Mental Health 
Research Institute, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff 
University, Cardiff, UK. 
CONVERGE Consortium Authorship 
Na Cai 1*, Tim Bigdeli 2*, Warren Kretzschmar 1*, Yihan Li 1*, Jieqin Liang 3, Li Song 3, Jingchu Hu 3, 
Qibin Li 3, Wei Jin 3, Zhenfei Hu 3, Guangbiao Wang 3, Linmao Wang 3, Puyi Qian 3, Yuan Liu 3, Tao Jiang 
3, Yao Lu 3, Xiuqing Zhang 3, Ye Yin 3, Yingrui Li 3, Xun Xu 3, Xiangchao Gan 4, Mark Reimers 2, Todd 
Webb 2, Brien Riley 2, Silviu Bacanu 2, Roseann E Peterson 2, Yiping Chen 5, Hui Zhong 6, Zhengrong Liu 
7, Gang Wang 8, Jing Sun 9, Hong Sang 10, Guoqing Jiang 11, Xiaoyan  Zhou 11, Yi Li 12,13, Wei Zhang 
14, Xueyi Wang 15, Xiang Fang 16, Runde Pan 17, Guodong Miao 18, Qiwen Zhang 19, Jian Hu 20, 
Fengyu Yu 21, Bo Du 22, Wenhua Sang 22, Keqing Li 22, Guibing Chen 23, Min Cai 24, Lijun Yang 25, 
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Kerang Zhang 38, Ning Sun 38, Youhui Li 39, Qihui Niu 39, Yutang Zhang 40, Tieqiao Liu 41, Chunmei Hu 
42, Zhen Zhang 43, Luxian Lv 44, Jicheng Dong 45, Xiaoping Wang 46, Ming Tao 47, Xumei Wang 48, Jing 
Xia 48, Han Rong 49, Qiang He 50, Tiebang Liu 51, Guoping Huang 52, Qiyi Mei 53, Zhenming Shen 54, 
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Ying Liu 55, Jianhua Shen 56, Tian Tian 56, Xiaojuan Liu 57, Wenyuan Wu 58, Danhua Gu 59, Guangyi Fu 
1, Yi Li 12,13, Jianguo Shi 60, Yunchun Chen 61, Jingfang Gao 62, Lanfen Liu 63, Lina Wang 63, Fuzhong 
Yang 64, Enzhao Cong 64, Jonathan Marchini 65,1, Huanming Yang 3, Jian Wang 3, Shenxun Shi 66,64, 
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1 Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, 
Oxfordshire, OX3 7BN, United Kingdom; 2 Virginia Institute for Psychiatric and Behavioral Genetics, 
Virginia Commonwealth University, Richmond, Virginia, 23298, USA; 3 BGI-Shenzhen, Floor 9 Complex 
Building, Beishan Industrial Zone, YantianDistrict,  Shenzhen, Guangdong, 518083, China; 4 Department 
of Comparative Developmental Genetics, Max Planck Institute for Plant Breeding Research, Carl-von-
Linne-Weg 10, Cologne, 50829, Germany; 5 CTSU, Richard Doll Building, University of Oxford, Old Road 
Campus, Oxford, Oxfordshire, OX3 7LF, United Kingdom; 6 Anhui Mental Health Center, No.316 
Huangshan Road, Hefei, Anhui, 230000, China; 7 Anshan Psychiatric Rehabilitation Hospital, No.127 
Shuangshan Road,Lishan District, Anshan, Liaoning, 114000, China; 8 Beijing Anding Hospital of Capital 
University of Medical Sciences, No.5 Ankang Hutong, Deshengmen wai, Xicheng District, Beijing, Beijing, 
100000, China; 9 Brain Hospital of Nanjing Medical University, No.264 Guangzhou Road, Nanjing, 
Jiangsu, 210000, China; 10 Changchun Mental Hospital, No.4596 Beihuan Road, Changchun, Jilin, 
130000, China; 11 Chongqing Mental Health Center, No.102 Jinzishan,Jiangbei District, Chongqing, 
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116000, China; 13 Wuhan Mental Health Center, No.70, Youyi Road, Wuhan, Hubei, 430000, China; 14 
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Mental Health Center, No.572 Dongfeng Road, Baoding, Hebei, 71000, China; 23 Huaian No.3 Hospital, 
No.272 West Huaihai Road, Huaian, Jiangsu, 223001, China; 24 Huzhou No.3 Hospital , No.255 Gongyuan 
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272000, China; 27 Liaocheng No. 4 Hospital, No.47 North Huayuan Road, Liaocheng, Shandong, 252000, 
China; 28 Mental Health Center of Shantou University, No.243 Daxue Road, Shantou, Guangdong, 
515000, China; 29 Mental Health Center of West China Hospital of Sichuan University, No.28 South 
Dianxin Street, Wuhou District, Chengdu, Sichuan, 610000, China; 30 Mental Health Institute of Jining 
Medical College, Dai Zhuang, Bei Jiao, Jining, Shandong, 272000, China; 31 Mental Hospital of Jiangxi 
Province, No.43 Shangfang Road, Nanchang, Jiangxi, 330000, China; 32 Mudanjiang Psychiatric Hospital 
of Heilongjiang Province, Xinglong, Mudanjiang, Heilongjiang, 157000, China; 33 Ningbo Kang Ning 
Hospital, No.1 Zhuangyu Road ,Zhenhai District, Ningbo, Zhejiang, 315000, China; 34 No. 3 Hospital of 
Sun Yat-sen University, No.600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, 510630, China; 35 
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